Key Highlights

  • Curis (NASDAQ:CRIS) finished Tuesday, November 10, 2026 at USD 0.5755, a 17.50% decline from a calculated prior close of USD 0.6976, or USD 0.1221 per share.
  • Volume was 480,790 shares, just 0.02 times average, while the calculated Market Value was near USD 3.84 million on about 6.7 million shares.
  • The shares sit 36.5% under the USD 0.9065 close of November 6, 2026, and 42.5% beneath the USD 1.00 Nasdaq minimum bid, both calculated.
  • Trailing diluted EPS is a loss of USD 14.29, a loss 85.37% narrower year over year, and the one-year share price change is a drop of 96.9%.

What Moved Curis on November 10 (-17.50%)

On Tuesday, November 10, 2026, Curis (NASDAQ:CRIS) ended the day at USD 0.5755, lower by 17.50%. Basic arithmetic on the published move gives a prior close of USD 0.6976 for Monday, November 9, marked as calculated. On Friday, November 6, 2026 the stock closed at USD 0.9065, then dropped 13.73% after hours to USD 0.7820 on about 10.3 times normal volume. A filing that day stated that the stock had stayed under USD 1.00 for 30 days and that Nasdaq delisting could follow with no compliance period. Tuesday therefore continued a slide that started before the weekend, and the Nasdaq listing was confirmed from published quote pages.

The Rationale: No New Catalyst Identified

Published coverage identified no company release or filing dated November 9 or 10, 2026, so saying no catalyst was found is the accurate description of the session itself. Dated context includes the November 2, 2026 proxy that set a reverse split vote for November 18, 2026, at a ratio from 1-for-5 to 1-for-25. A private Placement of about USD 8.5 million sold 16,666,680 shares or pre-funded warrants at an effective USD 0.51 each, with warrants at USD 0.60. By way of general context, shares tend to gravitate toward a financing price when new Supply is large and the listing is at risk. That is not confirmed for today.

Valuation, Liquidity and Risks Around USD 0.5755

The price stands USD 0.0655 over the USD 0.51 placement price, calculated. A published 10-Q headline cited a loss of USD 32.8 million and a going-concern warning, and 2025 Operating Cash Flow was negative USD 27.2 million. Management has said cash lasts through first leukemia data from 5 to 10 patients, due in December 2026, and third-quarter results are due on November 12, 2026 at 4:00 p.m. ET. The one-year share price change was a drop of 96.9%. A reverse split alters the share count and price but not market value, and a failed vote or data setback would lift delisting risk. With a market value near USD 3.84 million, a few trades can shift the price, spreads can be wide, and the move implies nothing about further direction for Canadian investors or anyone else.

Where Things Stand

Curis (NASDAQ:CRIS) lost 17.50% on November 10, 2026 with no new catalyst identified, following a Nasdaq bid-price warning and a heavy financing overhang. The USD 0.5755 close compares with a calculated USD 0.6976 prior close and a USD 0.9065 close on November 6. Key dates are results on November 12 and the reverse split vote on November 18. Nothing here implies the decline will continue or reverse.